Röder B, Nitschke L (2023)
Publication Type: Journal article
Publication year: 2023
Article Number: 152328
DOI: 10.1016/j.semarthrit.2023.152328
Background: B-cell activation is triggered by the B-cell receptor, but is also controlled by inhibitory receptors, which limit the BCR signaling. CD22 (Siglec-2) and Siglec-G are such inhibitory receptors expressed on B cells. CD22- or Siglec-G deficient mice show enhanced B cell activation. Objectives: It was the objective of our study to investigate the role of these inhibitory receptors in autoimmune disease and leukemia. Results: Ageing Siglec-G deficient or CD22 x Siglec-G deficient mice develop an SLE-like autoimmune disease with autoantibodies and kidney nephritis. In a mouse model for chronic lymphocytic leukemia (CLL), Siglec-G deficient mice show an earlier and more severe disease. Author's conclusions: These results show that Siglec-G and CD22 are both involved in preventing autoimmune diseases and leukemia delevopment and could therefore be attractive new targets.
APA:
Röder, B., & Nitschke, L. (2023). The role of Siglec-G on B cells in autoimmune disease and leukemia. Seminars in Arthritis and Rheumatism. https://doi.org/10.1016/j.semarthrit.2023.152328
MLA:
Röder, Bettina, and Lars Nitschke. "The role of Siglec-G on B cells in autoimmune disease and leukemia." Seminars in Arthritis and Rheumatism (2023).
BibTeX: Download